Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense
Stoke Therapeutics, Inc. (STOK) reported Share-based Payment Arrangement, Expense of $10.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-03
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $10.80M, a 42.17% increase year-over-year.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $8.75M, a 29.62% increase year-over-year.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $9.85M, a 37.95% increase year-over-year.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $8.04M, a 7.27% increase year-over-year.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $32.24M, a 17.36% increase from fiscal 2024.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $27.47M, a 8.76% increase from fiscal 2023.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $25.26M, a 10.51% increase from fiscal 2022.
- Stoke Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $22.85M, a 38.93% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.80M 10-Q · filed 2026-08-03 | $19.55M 10-Q · filed 2026-08-03 | $29.40M derived: sum of 3 quarters · filed 2026-08-03 | $37.44M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $8.75M 10-Q · filed 2026-05-07 | $18.60M derived: sum of 2 quarters · filed 2026-05-07 | $26.64M derived: sum of 3 quarters · filed 2026-05-07 | $34.24M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $9.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $17.89M derived: sum of 2 quarters · filed 2026-03-16 | $25.48M derived: sum of 3 quarters · filed 2026-08-03 | $32.24M 10-K · filed 2026-03-16 |
| 2025-09-30 | $8.04M 10-Q · filed 2025-11-04 | $15.64M derived: sum of 2 quarters · filed 2026-08-03 | $22.39M 10-Q · filed 2025-11-04 | $29.53M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $7.60M 10-Q · filed 2026-08-03 | $14.35M 10-Q · filed 2026-08-03 | $21.49M derived: sum of 3 quarters · filed 2026-08-03 | $28.98M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $6.75M 10-Q · filed 2026-05-07 | $13.89M derived: sum of 2 quarters · filed 2026-05-07 | $21.39M derived: sum of 3 quarters · filed 2026-05-07 | $28.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $14.63M derived: sum of 2 quarters · filed 2026-03-16 | $22.06M derived: sum of 3 quarters · filed 2026-03-16 | $27.47M 10-K · filed 2026-03-16 |
| 2024-09-30 | $7.49M 10-Q · filed 2025-11-04 | $14.92M derived: sum of 2 quarters · filed 2025-11-04 | $20.33M 10-Q · filed 2025-11-04 | $26.39M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $7.43M 10-Q · filed 2025-08-12 | $12.84M 10-Q · filed 2025-08-12 | $18.89M derived: sum of 3 quarters · filed 2025-08-12 | $25.45M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $5.41M 10-Q · filed 2025-05-13 | $11.47M derived: sum of 2 quarters · filed 2025-05-13 | $18.02M derived: sum of 3 quarters · filed 2025-05-13 | $24.78M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $12.61M derived: sum of 2 quarters · filed 2025-03-18 | $19.37M derived: sum of 3 quarters · filed 2025-03-18 | $25.26M 10-K · filed 2025-03-18 |
| 2023-09-30 | $6.55M 10-Q · filed 2024-11-05 | $13.31M derived: sum of 2 quarters · filed 2024-11-05 | $19.20M 10-Q · filed 2024-11-05 | $24.99M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $6.76M 10-Q · filed 2024-08-07 | $12.65M 10-Q · filed 2024-08-07 | $18.44M derived: sum of 3 quarters · filed 2024-08-07 | $24.36M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $5.89M 10-Q · filed 2024-05-06 | $11.68M derived: sum of 2 quarters · filed 2024-05-06 | $17.60M derived: sum of 3 quarters · filed 2024-05-06 | $23.77M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $11.72M derived: sum of 2 quarters · filed 2024-03-25 | $17.88M derived: sum of 3 quarters · filed 2024-03-25 | $22.85M 10-K · filed 2024-03-25 |
| 2022-09-30 | $5.93M 10-Q · filed 2023-11-07 | $12.09M derived: sum of 2 quarters · filed 2023-11-07 | $17.06M 10-Q · filed 2023-11-07 | $21.75M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $6.16M 10-Q · filed 2023-08-07 | $11.14M 10-Q · filed 2023-08-07 | $15.82M derived: sum of 3 quarters · filed 2023-08-07 | $20.44M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $4.97M 10-Q · filed 2023-05-04 | $9.66M derived: sum of 2 quarters · filed 2023-05-04 | $14.28M derived: sum of 3 quarters · filed 2023-05-04 | $18.73M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $9.30M derived: sum of 2 quarters · filed 2023-03-06 | $13.75M derived: sum of 3 quarters · filed 2023-03-06 | $16.45M 10-K · filed 2023-03-06 |
| 2021-09-30 | $4.61M 10-Q · filed 2022-11-14 | $9.07M derived: sum of 2 quarters · filed 2022-11-14 | $11.76M 10-Q · filed 2022-11-14 | $13.34M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.45M 10-Q · filed 2022-08-08 | $7.15M 10-Q · filed 2022-08-08 | $8.73M derived: sum of 3 quarters · filed 2022-08-08 | $10.52M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.70M 10-Q · filed 2022-05-10 | $4.28M derived: sum of 2 quarters · filed 2022-05-10 | $6.06M derived: sum of 3 quarters · filed 2022-05-10 | $7.71M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.37M derived: sum of 2 quarters · filed 2022-03-10 | $5.01M derived: sum of 3 quarters · filed 2022-03-10 | $5.77M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.78M 10-Q · filed 2021-11-08 | $3.43M derived: sum of 2 quarters · filed 2021-11-08 | $4.19M 10-Q · filed 2021-11-08 | $4.90M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $1.65M 10-Q · filed 2021-08-10 | $2.40M 10-Q · filed 2021-08-10 | $3.12M derived: sum of 3 quarters · filed 2021-08-10 | $3.85M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $754.00K 10-Q · filed 2021-05-10 | $1.47M derived: sum of 2 quarters · filed 2021-05-10 | $2.20M derived: sum of 3 quarters · filed 2021-05-10 | $2.50M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $712.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $1.44M derived: sum of 2 quarters · filed 2021-03-09 | $1.74M derived: sum of 3 quarters · filed 2021-03-09 | $1.92M 10-K · filed 2021-03-09 |
| 2019-09-30 | $731.00K 10-Q · filed 2020-11-12 | $1.03M derived: sum of 2 quarters · filed 2020-11-12 | $1.21M 10-Q · filed 2020-11-12 | $1.33M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $298.00K 10-Q · filed 2020-08-10 | $479.00K 10-Q · filed 2020-08-10 | $598.00K derived: sum of 3 quarters · filed 2020-08-10 | $638.00K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $181.00K 10-Q · filed 2020-05-15 | $300.00K derived: sum of 2 quarters · filed 2020-05-15 | $340.00K derived: sum of 3 quarters · filed 2020-05-15 | $417.00K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $159.00K derived: sum of 2 quarters · filed 2020-03-23 | $236.00K derived: sum of 3 quarters · filed 2020-03-23 | $240.00K 10-K · filed 2020-03-23 |
| 2018-09-30 | $40.00K 10-Q · filed 2019-11-12 | $117.00K derived: sum of 2 quarters · filed 2019-11-12 | $121.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $77.00K 10-Q · filed 2019-08-14 | $81.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |